DMAC long strategyA analysis of DMAC in a multi-year chart run to see if market downward pressure is substantial enough overshadow the upcoming catalyst for DMAC in the coming weeks.
Key stats
Market capitalization
42.309MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.50USD
About DiaMedica Therapeutics Inc
ISIN
CA25253X2077
Sector
Health Technology
Industry
Pharmaceuticals: Major
Website
diamedica.com
CEO
Rick John Pauls
Headquarters
Minneapolis
Employees
15
Founded
2000
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.
DMAC price may climb as it breaks lower Bollinger Band on Jul 10This price move could be a signal that DMAC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. Tickeron A.I.dvisor backtested 34 similar cases where DMAC's price broke its lower Bollinger Band, and 33 of them led to a
See all ideas
DMACDiaMedica struggles with trial results
DiaMedica Therapeutics slips 32% in the first three hours of Tuesday trading despite encouraging results out of its latest chronic kidney disease trial.
See all events
Income Statement
Balance Sheet
Cash Flow
Earnings
Next:—
0
Revenue
0